Cardiac Biomarkers.

Slides:

Advertisements

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Advertisements

for the TRAPID-AMI Investigators

Syncope & serial troponins don’t mix Cost Containment Project June 2015 Alex Raufi PGY2.

How can new diagnostic methods contribute in healthcare? What are doctors looking for? Better support in their clinical decision makings, which includes:

Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,

A view of Novel Cardiac Biomarkers in Heart Failure.

The Value Of In-vitro Diagnostics Healthcare challenges in the 21 st century for governments & hospitals & how in-vitro diagnostics can contribute to overcoming.

Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):

Acute Heart Failure in Apical Ballooning Syndrome (Takotsubo/Stress Cardiomyopathy) Clinical Correlates and Mayo Clinic Risk Score Malini Madhavan, MBBS;

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

Women and Cardiovascular Disease

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Biomarkers that “guide” therapy

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.

Survival probability (%)

BNP in Heart Failure Azam Hadi MD 9/17/2018.

Emerging Concepts in Heart Failure

Stephen W. Waldo et al. JACC 2008;51:

Diabetes and Risk of CV Outcomes

Part III Lessons Learned: A Master Class in High-Sensitivity Troponin A Global Perspective.

Cardiac Troponin.

Biomarker-Driven Management of Sepsis and Antibiotics Evidence and Perspectives.

Diagnostic Algorithms for ACS and High-Sensitivity Troponin

Biomarkers in Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

Part II: It Takes a Team— Incorporating High-Sensitivity Troponin Into Clinical Care.

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

A Case Challenge: Anticoagulant Choices for Acute PE

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Heart Failure Prevention: Mission Impossible?

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Section A: Introduction

Are We Closer to Personalized Medicine in MS?

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Part I: A Sensible Approach to Sensitive Troponin

Nat. Rev. Cardiol. doi: /nrcardio

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Learning Objectives Current Practices in Ruling Out AMI.

Selected Highlights of the Latest Advances in PAH

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Advancing Acute Coronary Syndrome Assessment:

The Heart Failure Team Heart Failure Care Map First 24 hours.

G. Michael Felker et al. JCHF 2014;2:

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Editorial Heart Failure Clinics

Overcoming Clinical Inertia

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018

Division of Cardiovascular Diseases No relevant author disclosures

Principal recommendations

CAD and HF Often Coexist

Nicholas Wettersten, MD, Alan S. Maisel, MD

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,

Program Goals Background: Anticoagulation in Patients With VTE.

Contemporary Considerations in Biomarker-Guided Therapy

The Research Question Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are associated with many adverse outcomes HF and AF share.

Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment Josep Lupón,

HF-Related Hospitalization and Readmissions

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Spearman’s rank correlation between preoperative serum levels of BNP/NT-proBNP and expression of HIF-2 alpha and preoperative serum level of VEGF. There.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Presentation transcript:

Cardiac Biomarkers

Cost of Heart Failure to Society

Biomarkers in the Management of Heart Failure Challenges and Opportunities

BNP and NT-proBNP for Diagnosis or Exclusion of Heart Failure

Correlations of Natriuretic Peptides With Cardiac Structure and Function

The Differential Diagnosis of an Elevated BNP or NT-proBNP

BNP and NT-proBNP for Prognosis in Heart Failure

Biomarker-Guided Heart Failure Trials

Understanding Heterogeneous Results in “Guided Therapy” Trials

TIME CHF Cost-Effectiveness BNP-Guided Therapy

Dallas Heart Study

High-Sensitivity Troponin Use in Europe

Troponins and Risk Stratification in Stable Outpatient CAD

Secondary Prevention and Prognostic Value of High-Sensitivity Troponins

Biomarker Assessments in Stable Patients With T2DM Observations From the SAVOR-TIMI 53 Trial

ADVANCE Trial

Cardiovascular Mortality Risk According to Number of Elevated Biomarkers

Additive Value of ST2 to NT-proBNP in Long-Term Prognosis

Prognosis Value of BNP/NT-proBNP Based on Timing of Measurement During Index Hospitalization for Acute HF

Therapies That Affect B-Type Natriuretic Peptide Levels

Neprilysin Inhibition A New Paradigm for HF Care?

LCZ696 and Biomarkers

Biomarkers and Risk Assessment

AMI

6 Million Chest Pain Visits Evaluated Annually in the United States

Can We Do Better?

Three Clinical Evaluation Tools

APACE hs-cTnT 1-Hour Algorithm

Patient Inclusion/Exclusion Criteria

TRAPID-AMI Results Presented at ESC 2014

Clinical Implications

Could Older Adults Be at Greater Risk of a “False Positive” Diagnosis of AMI?

Key Clinical Points

References

References (cont)

References (cont)

References (cont)

References (cont)